Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Vandetanib launched in U.S. for advanced medullary thyroid cancer

May 2, 2011

First selective ganglioside biosynthesis inhibitors identified at Zacharon Pharma

May 2, 2011

New lysophospholipid receptor antagonists reported by Amira Pharma

May 2, 2011

MK-3475 enters phase I trial in patients with solid tumors

May 2, 2011

CH-4938056 targets microtubule-associated protein 4 to confer antitumor activity

May 2, 2011

FDA approves Zytiga in combination with prednisone for metastatic CRPC

April 29, 2011

Adherex Technologies enrolls first patient in phase II eniluracil trial

April 29, 2011

AY-4 inhibits tumor growth in model of head and neck cancer

April 29, 2011

Antibody-drug conjugate BAY-94-9343 is active against mesothelin-expressing tumors

April 29, 2011

Second-generation tumor metabolism inhibitor PENAO shows promise in vitro and in vivo

April 29, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...